Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application 210934 for Sotagliflozin Oral Tablet
Summary

The Food and Drug Administration FDA announces a forthcoming public advisory committee meeting of the Endocrinologic and Metabolic Drugs Advisory Committee the Committee. The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Add your own comment! Browse all existing comments